Slate Bio is an immunotherapeutics development company that develops therapeutic solutions for autoimmune diseases.
Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 19, 2021 | Seed | $1.75M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
VTC Seed Fund | — | Seed |